[{"id":"0d66ff1a-e55f-44cf-ba5f-8c807ab496f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03084237","created_at":"2021-01-17T17:32:05.377Z","updated_at":"2024-07-02T16:35:02.787Z","phase":"Phase 3","brief_title":"Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer","source_id_and_acronym":"NCT03084237","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Hercessi (trastuzumab-strf)"],"overall_status":"Completed","enrollment":" Enrollment 652","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/23/2018","primary_completion_date":" 11/23/2018","study_txt":" Completion: 09/28/2021","study_completion_date":" 09/28/2021","last_update_posted":"2024-05-17"}]